| Product Name |
CAS NO. |
System support |
Document support |
Classification |
| (1S)-1,5-Anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol tetraacetate |
866607-35-4 |
ISO/ GMP |
TDP/DMF |
Canagliflozin hemihydrate |
| 2-(4-Fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene |
898566-17-1 |
ISO/ GMP |
TDP |
Canagliflozin hemihydrate |
| Dapagliflozin base |
461432-26-8 |
ISO/ GMP |
TDP/DMF |
Dapagliflozin propanediol monohydrate |
| (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol tetraacetate |
461432-25-7 |
ISO/ GMP |
TDP/DMF |
Dapagliflozin propanediol monohydrate |
| Methyl 1-C-[4-chloro-3-(4-ethoxybenzyl)phenyl]-α-D-glucopyranoside |
714269-57-5 |
ISO |
TDP |
Dapagliflozin propanediol monohydrate |
| 5-bromo-2-chloro-4’-ethoxydiphenylmethane |
461432-23-5 |
ISO |
TDP |
Dapagliflozin propanediol monohydrate |
| (5-Bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone |
461432-22-4 |
ISO |
TDP |
Dapagliflozin propanediol monohydrate |
| 5-iodo-2-chloro-4'-ethoxydiphenylmethane |
1103738-29-9 |
ISO |
TDP |
Dapagliflozin propanediol monohydrate |
| 5-Bromo-2-chlorobenzoic acid |
21739-92-4 |
ISO |
TDP |
Dapagliflozin propanediol monohydrate |
| (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol tetraacetate |
915095-99-7 |
ISO/ GMP |
TDP/DMF |
Empagliflozin |
| Methyl 1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-alpha-D-glucopyranoside |
1279691-36-9 |
ISO |
TDP |
Empagliflozin |
| (3S)-3-[4-[(5-Bromo-2-chlorophenyl)methyl]phenoxy]tetrahydro-furan |
915095-89-5 |
ISO |
TDP |
Empagliflozin |
| (3S)-3-[4-[(5-iodo-2-chlorophenyl)methyl]phenoxy]tetrahydro-furan |
915095-94-2 |
ISO |
TDP |
Empagliflozin |
| (2-Chloro-5-iodophenyl)[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methanone |
915095-87-3 |
ISO |
TDP |
Empagliflozin |
| 2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone |
32384-65-9 |
ISO |
TDP |
Empagliflozin |
| (S)-(+)-3-Hydroxytetrahydrofuran |
86087-23-2 |
ISO |
TDP |
Empagliflozin |
| Methyl (5S)-5-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-thio-beta-L-xylopyranoside 2,3,4-triacetate |
1018899-03-0 |
ISO/ GMP |
TDP/DMF |
Sotagliflozin |
| (4-Chloro-3-(4-ethoxybenzyl)phenyl)((3aS,5R,6S,6aS)-6-hydroxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methanone |
1103738-30-2 |
ISO |
TDP |
Sotagliflozin |
| (5S)-4,5-O-(1-Methylethylidene)-1-C-4-morpholinyl-D-xylo-pentodialdo-5,2-furanose |
1103738-19-7 |
ISO |
TDP |
Sotagliflozin |
| Ipragliflozin |
761423-87-4 |
ISO/ GMP |
TDP/DMF |
Ipragliflozin |
| (1S)-1,5-Anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-D-glucitol 2,3,4,6-tetraacetate |
1034305-21-9 |
ISO/ GMP |
TDP/DMF |
Ipragliflozin |
| 2-(5-Bromo-2-fluorobenzyl)benzo[b]thiophene |
1034305-17-3 |
ISO |
TDP |
Ipragliflozin |
| (2S,3R,4S,5S)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6,6-bis(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol |
1528636-39-6 |
ISO |
TDP |
Ertugliflozin |
| (S)-2-((2-Oxo-3-(4-(3-oxomorpholino)phenyl)oxazolidin-5-yl)methyl)isoindoline-1,3-dione |
446292-08-6 |
ISO |
TDP |
Rivaroxaban |
| (S)-4-(4-(5-(Aminomethyl)-2-oxooxazolidin-3-yl)phenyl)morpholin-3-one.HCl |
898543-06-1 |
ISO |
TDP |
Rivaroxaban |
| 2-[(2R)-2-Hydroxy-3-[[4-(3-oxo-4-morpholinyl)phenyl]amino]propyl]-1H-isoindole-1,3(2H)-dione |
446292-07-5 |
ISO |
TDP |
Rivaroxaban |
| (S)-(+)-N-(2,3-Epoxypropyl)phthalimide |
161596-47-0 |
ISO |
TDP |
Rivaroxaban |
| 4-(4-aminophenyl)morpholin-3-one |
438056-69-0 |
ISO |
TDP |
Rivaroxaban |
| 5-Chloro-2-thiophenecarboxylic acid |
24065-33-6 |
ISO |
TDP |
Rivaroxaban |
| Benzeneazomalononitrile |
6017-21-6 |
ISO |
TDP |
Riociguat |
| Pyrazolo[3,4-b]pyridine-3-carboximidamide,1-[(2-fluorophenyl)methyl]-, monohydrochloride |
256499-19-1 |
ISO |
TDP |
Riociguat |
| 5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carbonitrile |
1350653-26-7 |
ISO |
TDP |
Vericiguat |
| 4-Chloro-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine |
479633-63-1 |
ISO |
TDP |
Tofacitinib |
| 4-chloro-7H-pyrrolo[2,3-d]pyriMidine |
3680-69-1 |
ISO |
TDP |
Tofacitinib |
| Pyrrolo[2,3-d]pyrimidin-4-ol |
3680-71-5 |
ISO |
TDP |
Tofacitinib |
| 2-[1-(Ethylsulfonyl)-3-azetidinylidene]acetonitrile |
1187595-85-2 |
ISO |
TDP |
Baricitinib |
| tert-butyl 4-chloro-7H-pyrrolo[2,3-d]pyrimidine-7-carboxylate |
1236033-21-8 |
ISO |
TDP |
Baricitinib |
| Abrocitinib |
1622902-68-4 |
ISO |
TDP |
Abrocitinib |
| benzyl ((1s,3s)-3-(methylamino)cyclobutyl)carbamate hydrochloride |
2204290-99-1 |
ISO |
TDP |
Abrocitinib |
| N-(5-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide |
1142943-96-1 |
ISO |
TDP |
Filgotinib |
| 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)thiomorpholine 1,1-dioxide |
1092563-25-1 |
ISO |
TDP |
Filgotinib |
| (4-Chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methylpivalate |
1146629-75-5 |
ISO |
TDP |
Ruxolitinib |
| 1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole |
1029716-44-6 |
ISO |
TDP |
Ruxolitinib |
| 3-Cyclopentyl-acrylonitrile |
591769-05-0 |
ISO |
TDP |
Ruxolitinib |
| benzyl (2S,5R)-5-amino-2-methylpiperidine-1-carboxylate hydrogen chloride |
1207853-23-3 |
ISO |
TDP |
Ritlecitinib |
| (S)-1-(2,6-Dichloro-3-fluorophenyl)ethanol |
877397-65-4 |
ISO |
TDP |
Crizotinib |
| (R)-5-broMo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-aMine |
877399-00-3 |
ISO |
TDP |
Crizotinib |
| tert-Butyl 4-[4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]piperidine-1-carboxylate |
877399-74-1 |
ISO |
TDP |
Crizotinib |
| (R)-2-(2,5-difluorophenyl)pyrrolidine (R)-2-hydroxysuccinate |
1919868-77-1 |
ISO |
TDP |
Larotrectinib |
| (S)-pyrrolidin-3-ol |
100243-39-8 |
ISO |
TDP |
Larotrectinib |
| (S)-1-(5-fluoro-2-iodophenyl)ethan-1-ol |
1454847-96-1 |
ISO |
TDP |
Lorlatinib |
| (R)-pyrrolidin-3-ol |
2799-21-5 |
ISO |
TDP |
Asciminib |
| 4-(Chlorodifluoromethoxy)aniline |
39065-95-7 |
ISO |
TDP |
Asciminib |
| 5-Chloro-2-((R)-5-Methyl-[1,4]diazepan-1-yl)benzooxazole hydrochloride |
1266664-66-7 |
ISO |
TDP |
Suvorexant |
| 4-((2-aminoethyl)(5-chlorobenzo[d]oxazol-2-yl)amino)butan-2-onedimethanesulfonate |
1276666-12-6 |
ISO |
TDP |
Suvorexant |
| (R)-1-benzyl-5-methyl-1,4-diazepane |
1620097-06-4 |
ISO |
TDP |
Suvorexant |
| 5-Methyl-2-(2H-1,2,3-triazol-2-yl)benzoicacid |
956317-36-5 |
ISO |
TDP |
Suvorexant |
| 5-bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine |
380380-64-3 |
ISO |
TDP |
Tedizolid |
| 1H-IMidazole, 5,5'-[1,1'-biphenyl]-4,4'-diylbis[2-(2S)-2-pyrrolidinyl-, hydrochloride (1:4) |
1009119-83-8 |
ISO |
TDP |
Tedizolid |
| (R)-3-(4-bromo-3-fluorophenyl)-5-(hydroxymethyl)oxazolidin-2-one |
444335-16-4 |
ISO |
TDP |
Tedizolid |
| Torezolid |
856866-72-3 |
ISO |
TDP |
Tedizolid |
| (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol dihydrochloride |
1373116-07-4 |
ISO |
TDP |
Rimegepant sulfate |
| (9R)-9-hydroxy-6,7,8,9-tetrahydrocyclohepta[b]pyridin-5-one |
1190363-44-0 |
ISO |
TDP |
Rimegepant sulfate |
| 1-(1-(1H-imidazole-1-carbonyl)piperidin-4-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one |
1373116-06-3 |
ISO |
TDP |
Rimegepant sulfate |
| 2-Oxo-1-(4-piperidinyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridine dihydrochloride |
781649-84-1 |
ISO |
TDP |
Rimegepant sulfate |
| 3-(piperidin-4-yl)quinolin-2(1h)-one hydrochloride |
855778-84-6 |
ISO |
TDP |
Zevagepant |
| methyl (2R)-2-amino-3-(7-methyl-1H-indazol-5-yl)propanoate dihydrochloride |
1414976-14-9 |
ISO |
TDP |
Zevagepant |
| 1-(1-Methyl-4-piperidinyl)piperazine |
23995-88-2 |
ISO |
TDP |
Zevagepant |
| 2-Chloropyridine-3-sulfonyl chloride |
6684-06-6 |
ISO |
TDP |
Zibotentan |
| isobutyl 3-Methoxy-5-Methylpyrazin-2-ylcarbaMate |
186497-47-2 |
ISO |
TDP |
Zibotentan |
| [4-(1,3,4-oxadiazol-2-yl)phenyl]boronic acid |
276694-22-5 |
ISO |
TDP |
Zibotentan |
| 1-isopropylpyrimidine-2,4,6(1H,3H,5H)-trione |
69998-14-7 |
ISO |
TDP |
Mavacamten |
Home
Product
News
Contact
